The CKD bowel health study: understanding the bowel health and gastrointestinal symptom management in patients with chronic kidney disease: a mixed-methods observational longitudinal study (protocol).
Chronic kidney disease
Dialysis
Discrete choice experiment
Gastrointestinal symptoms
Gut microbiome
Gut microbiota
Kidney transplant
Observational longitudinal study
Qualitative interview
Uremic toxins
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
21 11 2021
21 11 2021
Historique:
received:
30
07
2021
accepted:
04
11
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
24
2
2022
Statut:
epublish
Résumé
Gastro-intestinal (GI) intolerance is a frequently reported outcome in patients with kidney failure receiving maintenance dialysis and those who have received kidney transplants. Symptoms of GI intolerance (diarrhoea, constipation, bloating, abdominal pain, heart burn, and reflux) are associated with significant reduction in quality of life, morbidity, and increased used of healthcare resources. Having chronic kidney disease (CKD), together with related changes in diet and medication, may alter the gut microbiota and the microbial-derived uraemic metabolites that accumulate in kidney failure, and contribute to various complications including chronic diarrhoea, opportunistic infections, and drug-related colitis. Despite the high disease burden among patients with kidney replacement therapies, GI symptoms are often under-recognised and, consequently limited resources and strategies are devoted to the management of gastrointestinal complications in patients with CKD. The CKD Bowel Health Study is a multi-centre mixed-methods observational longitudinal study to better understand the bowel health and GI symptom management in patients with CKD. The program comprises of a longitudinal study that will assess the burden and risk factors of GI intolerance in patients treated with maintenance dialysis; a semi-structured interview study that will describe experiences of GI intolerance (including symptoms, treatment, self-management) in transplant candidates and recipients; and a discrete choice experience to elicit patient preferences regarding their experiences and perspectives of various intervention strategies for the management of GI symptoms after kidney transplantation. This proposed program of work aims to define the burden the GI intolerance in patients with kidney failure and generate evidence on the patients' experiences of GI intolerance and their perspectives on their clinical and own management strategies of these symptoms, ensuring a patient-centred approach to guide clinical decision making and to inform the best study design for intervention trials. This study is registered on the Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000548831 . This study has been approved by the Western Sydney Local Health District Human Research Ethics Committee of New South Wales Health (HREC ETH03007). This study is supported by a National Health and Medical Research Council (NHMRC) Australia Investigator Grant (APP1195414), and an NHMRC Australia Postgraduate Scholarship (APP2005244).
Sections du résumé
BACKGROUND
Gastro-intestinal (GI) intolerance is a frequently reported outcome in patients with kidney failure receiving maintenance dialysis and those who have received kidney transplants. Symptoms of GI intolerance (diarrhoea, constipation, bloating, abdominal pain, heart burn, and reflux) are associated with significant reduction in quality of life, morbidity, and increased used of healthcare resources. Having chronic kidney disease (CKD), together with related changes in diet and medication, may alter the gut microbiota and the microbial-derived uraemic metabolites that accumulate in kidney failure, and contribute to various complications including chronic diarrhoea, opportunistic infections, and drug-related colitis. Despite the high disease burden among patients with kidney replacement therapies, GI symptoms are often under-recognised and, consequently limited resources and strategies are devoted to the management of gastrointestinal complications in patients with CKD.
METHODS
The CKD Bowel Health Study is a multi-centre mixed-methods observational longitudinal study to better understand the bowel health and GI symptom management in patients with CKD. The program comprises of a longitudinal study that will assess the burden and risk factors of GI intolerance in patients treated with maintenance dialysis; a semi-structured interview study that will describe experiences of GI intolerance (including symptoms, treatment, self-management) in transplant candidates and recipients; and a discrete choice experience to elicit patient preferences regarding their experiences and perspectives of various intervention strategies for the management of GI symptoms after kidney transplantation.
DISCUSSION
This proposed program of work aims to define the burden the GI intolerance in patients with kidney failure and generate evidence on the patients' experiences of GI intolerance and their perspectives on their clinical and own management strategies of these symptoms, ensuring a patient-centred approach to guide clinical decision making and to inform the best study design for intervention trials.
TRIAL REGISTRATION
This study is registered on the Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000548831 . This study has been approved by the Western Sydney Local Health District Human Research Ethics Committee of New South Wales Health (HREC ETH03007). This study is supported by a National Health and Medical Research Council (NHMRC) Australia Investigator Grant (APP1195414), and an NHMRC Australia Postgraduate Scholarship (APP2005244).
Identifiants
pubmed: 34802445
doi: 10.1186/s12882-021-02600-x
pii: 10.1186/s12882-021-02600-x
pmc: PMC8606224
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
388Informations de copyright
© 2021. The Author(s).
Références
J Immunol Res. 2014;2014:586939
pubmed: 25147831
Am J Kidney Dis. 2015 Mar;65(3):443-50
pubmed: 25304984
Qual Life Res. 1998 Jan;7(1):75-83
pubmed: 9481153
BMJ Open. 2017 Jan 19;7(1):e013829
pubmed: 28104711
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Transpl Int. 2010 Nov;23(11):1126-34
pubmed: 20525020
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Transplantation. 2010 Feb 27;89(4):446-51
pubmed: 20177347
Health Qual Life Outcomes. 2008 Jul 21;6:53
pubmed: 18644133
Clin J Am Soc Nephrol. 2018 Jan 6;13(1):100-108
pubmed: 29051145
Patient Prefer Adherence. 2018 Jul 04;12:1175-1191
pubmed: 30013329
Pharmacoeconomics. 2017 Jul;35(7):697-716
pubmed: 28374325
Clin Transplant. 2005 Dec;19(6):779-84
pubmed: 16313325
PLoS One. 2019 Dec 19;14(12):e0225722
pubmed: 31856215
Br J Surg. 1995 Feb;82(2):216-22
pubmed: 7749697
Public Health Nutr. 2016 Sep;19(13):2357-68
pubmed: 27075344
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):443-453
pubmed: 28143863
Nat Rev Nephrol. 2019 Sep;15(9):531-545
pubmed: 31243394
J Heart Lung Transplant. 2008 Jan;27(1):72-7
pubmed: 18187090
Transplantation. 2014 Oct 15;98(7):697-705
pubmed: 25289916
J Am Soc Nephrol. 2019 Feb 14;:
pubmed: 30765426
J Neurogastroenterol Motil. 2013 Apr;19(2):137-48
pubmed: 23667745
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):223-31
pubmed: 26772193
BMC Nephrol. 2012 Nov 22;13:152
pubmed: 23173887
Am J Kidney Dis. 2015 Mar;65(3):384-93
pubmed: 25245301
Nephrol Dial Transplant. 2018 Feb 1;33(2):348-355
pubmed: 28158746
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
J Ren Nutr. 2018 Nov;28(6):411-421
pubmed: 29691161
J Am Soc Nephrol. 2003 Sep;14(9):2381-6
pubmed: 12937317
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):454-466
pubmed: 28223290
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
BMJ Open. 2018 Apr 20;8(4):e021198
pubmed: 29678992
Scand J Gastroenterol. 1995 Nov;30(11):1046-52
pubmed: 8578162
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715